Program leaders---cell and gene therapy

项目负责人——细胞与基因治疗

• 批准号: 8181352
• 负责人: MALCOLM K. BRENNER
• 金额: $ 1.78万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-17 至 2015-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8181352
• 关键词: Address; Adoptive Immunotherapy; Adult; Award; Biology; Cancer Center; Cells; Cellular biology; Childhood; Clinical; Clinical Research; Clinical Trials; Collaborations; Community Clinical Oncology Program; Core Facility; Cytotoxic T-Lymphocytes; Development; Ensure; Faculty; Funding; Genes; Goals; Good Clinical Practice; Graft-Versus-Tumor Induction; Grant; Hospitals; Human Genetics; Immune system; Immunity; Immunotherapy; Individual; Institution; Journals; Laboratories; Laboratory Study; Link; Lymphoma; Malignant - descriptor; Malignant Neoplasms; Manuscripts; Medicine; Methodist Church; Mission; Modality; Molecular; Molecular Immunology; Monoclonal Antibodies; Neuroblastoma; Operative Surgical Procedures; Orphan Drugs; Outcome; Pathology; Patients; Pediatric Hospitals; Pediatric Oncology; Pediatric Surgical Procedures; Pediatrics; Peer Review; Process; Production; Program Description; Protocols documentation; Publishing; Reagent; Recording of previous events; Regimen; Reporting; Reproduction spores; Research; Research Personnel; Resistance; Resource Sharing; Resources; Running; Satellite Viruses; Scientist; Series; Stem cell transplant; Stem cells; T-Lymphocyte; Testing; Texas; Transplantation; Tumor Antigens; Urology; Viral; Virus; Work; bench to bedside; cancer cell; cancer immunotherapy; cancer stem cell; cancer therapy; cell growth; college; conditioning; conventional therapy; gene therapy; genetic manipulation; graft vs host disease; improved; meetings; member; programs; reconstitution; stem cell biology; success; tumor; vector

The goals of the Cancer Cell and Gene Therapy (CCGT) Program are to incorporate advances in cellular and gene therapy into the treatment of cancer. The Cancer Center Program is a sub-component of the Center for Cell and Gene Therapy and has 18 research members from a multiple Departments at Baylor, including Medicine, Pediatrics, Pathology, Immunology and Molecular and Human Genetics. The program had a total of $6,315,268 support from the NCI last year and overall received $18,522,146 in peer reviewed funding. Members of the program published over 180 cancer related manuscripts in peer-reviewed journals of which 51% represented intraprogrammatic collaborations and 30% interprogrammatic. Our research focuses on normal and malignant stem cells, adoptive immunotherapy of cancer and on improving outcomes of stem cell transplantation for cancer. CCGT has basic, translational and clinical research components. Our basic investigators work on understanding the mechanisms by which normal and malignant stem cell growth is controlled, and on the molecular and cellular interactions involved in development of tumor vasculature and stroma. These researchers are also identifying new targets for immunotherapy, and optimizing presentation of weak tumor antigens to the immune system. Our translational investigators are moving cell and gene based therapies from the bench to the bedside in a series of small-scale iterative laboratory-clinical- laboratory protocols, and are also developing pivotal trials. We have a decade-long history of successful and timely implementation of clinical translational projects in gene and cellular therapy, and we have the resources to supply and test all the clinical reagents required, since our center is one of three national NHLBl-funded Production Assistance for Cellular Therapy centers. Major accomplishments include the demonstration of activity of virus specific cytotoxic T lymphocytes in virus-associated cancers (resulting in an orphan drug designation for EBV CTLs for post transplant lymphoma) and studies showing the antitumor activity of genetically modified T cells in subjects with neuroblastoma and lymphoma. Our clinical researchers run the adult and (in collaboration with the Pediatric Oncology program) pediatric hemopoietic stem cell transplant programs and are extending the applicability of transplantation for malignancy by using monoclonal antibodies in subablative conditioning regimens and using post transplant immunotherapy to reduce GVHD whilst augmenting graft versus tumor activity and reconstituting anti-viral immunity.

癌细胞和基因治疗（CCGT）计划的目标是将细胞生物学的进展 和基因疗法来治疗癌症。癌症中心计划是 中心的细胞和基因治疗，并有18个研究成员来自多个部门在贝勒， 包括医学、儿科学、病理学、免疫学、分子和人类遗传学。程序 去年，NCI总共提供了6，315，268美元的支持，在同行评审中总共收到了18，522，146美元 经费该项目的成员在同行评审期刊上发表了180多篇与癌症相关的手稿 其中51%是方案内合作，30%是方案间合作。我们的研究 专注于正常和恶性干细胞，癌症的过继免疫治疗和改善结果 干细胞移植治疗癌症CCGT包括基础、转化和临床研究。我们 基础研究人员致力于了解正常和恶性干细胞生长的机制， 是受控制的，并且依赖于参与肿瘤脉管系统发展的分子和细胞相互作用 和基质。这些研究人员还确定了免疫治疗的新靶点，并优化了 将弱肿瘤抗原呈递给免疫系统。我们的翻译研究人员正在移动细胞 和基于基因的治疗，从实验室到床边，在一系列小规模的迭代实验室-临床- 实验室协议，并正在开发关键试验。我们有十年之久的历史， 成功和及时地实施基因和细胞治疗的临床转化项目， 我有资源供应和测试所有临床试剂所需的，因为我们的中心是三个之一， 国家NHL资助的细胞治疗中心生产援助。主要成就包括 证实了病毒特异性细胞毒性T淋巴细胞在病毒相关癌症中的活性（导致 在移植后淋巴瘤的EBV CTL的孤儿药指定中）和显示抗肿瘤 神经母细胞瘤和淋巴瘤受试者中遗传修饰的T细胞的活性。我们的临床 研究人员运行成人和（与儿科肿瘤学项目合作）儿科造血干细胞移植。 干细胞移植计划，并正在扩大恶性肿瘤移植的适用性， 单克隆抗体在亚烧蚀预处理方案中的应用以及使用移植后免疫疗法， 减少GVHD，同时增强移植物抗肿瘤活性并重建抗病毒免疫。